CrystalGenomics Invites Co Ltd
083790
Company Profile
Business description
CrystalGenomics Invites Co Ltd Formerly CrystalGenomics Inc is one of the leading biopharmaceutical company in Korea. The company is mainly engaged in the research and development and new drug development. It develops innovative new drug development projects such as eradication antibiotics and molecular targeted anticancer drugs. It focuses on arthritic medicines and antibiotics which kill resistant bacteria. It also offers medicines for cancer, obesity, asthma, and diabetes.
Contact
5F, A-dong, Korea Bio Park
694-1, Sampyeong-dong, Bundang-gu
Seongnam-siGyeonggi463-400
KORT: +82 316282700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
80
Stocks News & Analysis
stocks
Strong result for ASX insurer but not the new norm
Stellar first half profits but increasing competition will lower future rate increases.
stocks
Eli Lilly earnings: Weak Orforglipron obesity data weighs down a strong quarter
With today’s share drop, we think Lilly stock looks fairly valued.
stocks
Solid 2025 for A-REIT but development activity will weigh on 2026
Positive news for income investors as yield exceeds 5%.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.10 | 31.50 | 0.35% |
| CAC 40 | 7,743.00 | 33.68 | 0.44% |
| DAX 40 | 24,162.86 | 29.64 | -0.12% |
| Dow JONES (US) | 44,175.61 | 206.97 | 0.47% |
| FTSE 100 | 9,095.73 | 5.04 | -0.06% |
| HKSE | 24,869.54 | 10.72 | 0.04% |
| NASDAQ | 21,450.02 | 207.32 | 0.98% |
| Nikkei 225 | 41,820.48 | 761.33 | 1.85% |
| NZX 50 Index | 12,938.70 | 94.07 | 0.73% |
| S&P 500 | 6,389.45 | 49.45 | 0.78% |
| S&P/ASX 200 | 8,837.20 | 30.10 | 0.34% |
| SSE Composite Index | 3,635.78 | 0.65 | 0.02% |